ABT Stock Overview
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide.
Abbott Laboratories Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$126.74|
|52 Week High||US$131.61|
|52 Week Low||US$105.32|
|1 Month Change||-1.71%|
|3 Month Change||-1.36%|
|1 Year Change||17.19%|
|3 Year Change||77.26%|
|5 Year Change||229.37%|
|Change since IPO||1,364.14%|
Recent News & Updates
Abbott: Vaccinate Your Portfolio With A Pandemic-Resistant Dividend Aristocrat
Abbott's Q3, 2021 exemplified its pandemic resistance. Abbott's COVID-19 testing has grown to a major contributor for Abbott, counterbalancing the pandemic challenges elsewhere in its business. Abbott has taken its punches as it has brought its COVID-19 testing business up to scale.
A Look At The Fair Value Of Abbott Laboratories (NYSE:ABT)
Today we will run through one way of estimating the intrinsic value of Abbott Laboratories ( NYSE:ABT ) by taking the...
We Like These Underlying Return On Capital Trends At Abbott Laboratories (NYSE:ABT)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...
Abbott Deserves To Be On Your Watchlist
Abbott smashed analysts’ third quarter estimates thanks to better-than-expected COVID-19 testing revenues and strong performance by all major divisions. The company’s Libre platform for diabetes management, recent approvals in key growth areas and several upcoming products are expected to drive future sales. While I am optimistic about Abbott based on its diversified business, strong fundamentals and growth prospects beyond COVID-19 testing, I have a Neutral stance owing to valuation concerns.
|ABT||US Medical Equipment||US Market|
Return vs Industry: ABT exceeded the US Medical Equipment industry which returned 10.8% over the past year.
Return vs Market: ABT underperformed the US Market which returned 20% over the past year.
|ABT Average Weekly Movement||2.7%|
|Medical Equipment Industry Average Movement||7.3%|
|Market Average Movement||6.0%|
|10% most volatile stocks in US Market||15.1%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: ABT is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: ABT's weekly volatility (3%) has been stable over the past year.
About the Company
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Abbott Laboratories Fundamentals Summary
|ABT fundamental statistics|
Is ABT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ABT income statement (TTM)|
|Cost of Revenue||US$18.26b|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||4.08|
|Net Profit Margin||17.04%|
How did ABT perform over the long term?See historical performance and comparison
1.4%Current Dividend Yield
Is Abbott Laboratories undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ABT ($126.74) is trading below our estimate of fair value ($155.87)
Significantly Below Fair Value: ABT is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: ABT is good value based on its PE Ratio (31.1x) compared to the US Medical Equipment industry average (45.4x).
PE vs Market: ABT is poor value based on its PE Ratio (31.1x) compared to the US market (16.8x).
Price to Earnings Growth Ratio
PEG Ratio: ABT is poor value based on its PEG Ratio (4.6x)
Price to Book Ratio
PB vs Industry: ABT is overvalued based on its PB Ratio (6.5x) compared to the US Medical Equipment industry average (3.7x).
How is Abbott Laboratories forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABT's forecast earnings growth (6.8% per year) is above the savings rate (2%).
Earnings vs Market: ABT's earnings (6.8% per year) are forecast to grow slower than the US market (14.2% per year).
High Growth Earnings: ABT's earnings are forecast to grow, but not significantly.
Revenue vs Market: ABT's revenue (2.9% per year) is forecast to grow slower than the US market (10.1% per year).
High Growth Revenue: ABT's revenue (2.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABT's Return on Equity is forecast to be high in 3 years time (23.2%)
How has Abbott Laboratories performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABT has high quality earnings.
Growing Profit Margin: ABT's current net profit margins (17%) are higher than last year (10.4%).
Past Earnings Growth Analysis
Earnings Trend: ABT's earnings have grown significantly by 41.4% per year over the past 5 years.
Accelerating Growth: ABT's earnings growth over the past year (115.4%) exceeds its 5-year average (41.4% per year).
Earnings vs Industry: ABT earnings growth over the past year (115.4%) exceeded the Medical Equipment industry 51.2%.
Return on Equity
High ROE: ABT's Return on Equity (20.9%) is considered high.
How is Abbott Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: ABT's short term assets ($23.5B) exceed its short term liabilities ($12.9B).
Long Term Liabilities: ABT's short term assets ($23.5B) do not cover its long term liabilities ($26.3B).
Debt to Equity History and Analysis
Debt Level: ABT's net debt to equity ratio (25.1%) is considered satisfactory.
Reducing Debt: ABT's debt to equity ratio has increased from 41.4% to 53.1% over the past 5 years.
Debt Coverage: ABT's debt is well covered by operating cash flow (61.2%).
Interest Coverage: ABT's interest payments on its debt are well covered by EBIT (17.8x coverage).
What is Abbott Laboratories's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ABT's dividend (1.42%) is higher than the bottom 25% of dividend payers in the US market (1.35%).
High Dividend: ABT's dividend (1.42%) is low compared to the top 25% of dividend payers in the US market (3.63%).
Stability and Growth of Payments
Stable Dividend: ABT's dividend payments have been volatile in the past 10 years.
Growing Dividend: ABT's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (44.4%), ABT's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: ABT's dividends in 3 years are forecast to be well covered by earnings (34.1% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Robert Ford (47 yo)
Mr. Robert B. Ford has been the Chief Executive Officer and Director of Abbott Laboratories since March 31, 2020. He has been President at Abbott Laboratories since October 15, 2018 and served as its Execu...
CEO Compensation Analysis
Compensation vs Market: Robert's total compensation ($USD20.45M) is above average for companies of similar size in the US market ($USD11.14M).
Compensation vs Earnings: Robert's compensation has increased by more than 20% in the past year.
Experienced Management: ABT's management team is considered experienced (2.3 years average tenure).
Experienced Board: ABT's board of directors are considered experienced (9.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Abbott Laboratories's employee growth, exchange listings and data sources
- Name: Abbott Laboratories
- Ticker: ABT
- Exchange: NYSE
- Founded: 1888
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$222.397b
- Shares outstanding: 1.77b
- Website: https://www.abbott.com
Number of Employees
- Abbott Laboratories
- 100 Abbott Park Road
- Abbott Park
- North Chicago
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/01 23:54|
|End of Day Share Price||2021/12/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.